AOD 9604 - Generic Peptides

Buy AOD 9604 by Generic Peptides at XSteroids. AOD 9604 is the fat-metabolism fragment of human growth hormone that actually reached human testing, produced a modest result and was then withdrawn from development, and the Generic Peptides version arrives as lyophilized powder in a 2 mg vial or a 5 mg vial. Because so much of its reputation rests on marketing rather than data, this page separates the trial record from the claims.

One clarification before the numbers. AOD 9604 was studied as an oral capsule and is not an approved medicine anywhere; the vial offered here is a lyophilized research powder and no approved human dose exists for it.

What AOD 9604 Is and What You Are Buying

The box holds one glass vial of white lyophilized powder, filled at 2 mg or 5 mg, closed with a stopper held by a crimp cap. The mixing kit is not part of the order: diluent, sterile water, syringes and swabs all come from separate purchases. Because two fills share this page, strength is chosen on the pack option and stays out of the product title.

The molecule is a 16-amino-acid chain copied from the tail of human growth hormone, residues 176 to 191, with one change: a tyrosine sits where the natural phenylalanine would be at the front end. Its sequence runs Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, closed by a disulfide bridge. Its formula is C78H123N23O23S2, its mass is near 1815 g/mol and its CAS number is 221231-10-3. This is not the same peptide as the unmodified HGH Frag 176-191 sold by Generic Peptides: the tyrosine substitution is what makes AOD 9604 the stabilised relative of that native tail.

How AOD 9604 Works

The beta-3 adrenergic route

In obese mice the peptide raises expression of beta-3 adrenergic receptors, the main receptor that drives fat breakdown in adipose tissue, while also damping new fat formation. The result is unusually clean: mice engineered without the beta-3 receptor do not respond to it at all, which is the strongest mechanistic evidence in the whole file. The receptor requirement explains both the promise and the limits of the compound.

Why it was separated from growth hormone

The commercial idea was to keep the lipolytic part of growth hormone and drop everything else. Early human work suggested that AOD 9604 retained lipolytic activity without pushing IGF-1 the way full growth hormone does, and avoiding that push was the entire selling point of the fragment. Later trial results did not support the commercial story strongly enough to keep the drug alive.

Pharmacokinetics and the missing profile

No human half-life is established in the sources used here, and no approved pharmacokinetic profile exists because the product never reached a label. In trials the peptide was given orally, where absorption is poor and variable, while the vial sold here is intended for laboratory use after reconstitution. That difference is worth remembering: the trial record belongs to a capsule, not to the powder in this pack.

What to Expect from AOD 9604 in Research

The clinical record is small and mixed. In a 12-week randomised study the peptide produced about 1.8 kg more weight loss than placebo, a difference that is real in statistical terms but modest in practice. A longer 24-week study did not show a sufficient lipolytic effect, and development was stopped in 2007. The programme ran from 2001 to 2007 after coming out of work at Monash University in the 1990s, and the Phase IIb trial missed its primary endpoint.

Everything vivid about AOD 9604 comes from animal work. The mouse studies, including the beta-3 knockout experiments, are where the clean fat-loss narrative originates. Human trials are where it stalled. There is no human body-composition dataset for the injected research vial, no published time course, and no measured marker that a buyer could reproduce at home. A waist tape, a scale and a food log will tell you more about your own plan than any claim on a vendor page.

One more expectation to set: nothing in the record suggests that AOD 9604 changes appetite or gastric emptying, because it does not act on the GLP-1 pathway. A comparison with the semaglutide class is therefore about the goal, not the mechanism.

AOD 9604 Dosing and Reconstitution

Mixing the 2 mg and 5 mg vials

Read the label, then read the water you add. Two millilitres in the 2 mg vial give 1 mg/ml, which makes 0.1 ml equal to 100 mcg and 10 syringe units; one millilitre instead concentrates the vial to 2 mg/ml, so those same 10 units carry 200 mcg. The 5 mg vial doubles the picture: 2 ml gives 2.5 mg/ml and 250 mcg per 10 units, while 1 ml gives 5 mg/ml and 500 mcg per 10 units. Swirl; never shake.

Amounts quoted in research

Supplier notes describe 250 to 500 mcg per day subcutaneously with cycles of 4 to 12 weeks, although there is no validated human protocol behind those figures. On that arithmetic a 2 mg vial lasts roughly 8 days at 250 mcg daily, and a 5 mg vial roughly 20 days. Buy a vial size that matches the cycle you actually intend to finish.

Stacking AOD 9604 With Other Generic Peptides

The closest relative is HGH Frag 176-191, the unmodified tail of the same hormone, and Adipotide approaches the same goal by targeting the blood supply of fat instead of its receptors. Somatropin is the full hormone reference point, while Tesamorelin covers the GH-releasing route with visceral fat data. In the appetite-driven group, Semaglutide and Tirzepatide work through gut and brain receptors, and AICAR is a metabolic research compound rather than a peptide. Not one of those pairings has been examined as a combination.

Recovery and Breaks Around AOD 9604

AOD 9604 is a fragment rather than a hormone, so testosterone production is not suppressed and no post-cycle protocol follows from it. The practical recovery question is different: how long to run the peptide and what to do between cycles. Supplier notes suggest 4 to 12 weeks of use with a break before repeating, and a break also gives a clean baseline for measuring whether anything changed. If the cycle includes a GH-releasing peptide such as Tesamorelin, that compound carries its own schedule and should be planned separately.

AOD 9604 Side Effects and Legal Status

Safety record

The clinical programme did not produce a licensed product, and the reason given when development stopped was lack of efficacy rather than a published safety signal. That is not the same as proof of safety: there is no approved label, no long-term human dataset and no post-marketing record. An injection under the skin can leave local redness, tenderness or swelling, as with any peptide.

Prohibited status in sport

Class S2.2.3 of the WADA Prohibited List names growth hormone fragments, AOD 9604 among them, and that class is banned at every hour of the year rather than only in competition. No country has approved the peptide for human use, and it is offered as a research product.

How to Keep AOD 9604: Storage Practice

Store the powder between 2 and 8 C with the light kept out, and move it to the freezer if storage will run into months. A solution made up from the powder stays at 2 to 8 C and must be finished within 28 to 30 days, without ever being frozen. Take the vial out early so it arrives at room temperature, and clean the stopper with an alcohol swab before each draw.

Why Buy AOD 9604 from XSteroids?

Generic Peptides AOD 9604 is carried at XSteroids in both fills inside the Generic Peptides category, so one order can cover a whole research plan. The HGH Frag 176-191 card shows the unmodified tail, and Adipotide is the comparison if the vascular route is the point. Use the arithmetic above to fix the fill, then finish the mixed solution inside its 30-day limit.